The Center for Optimal Health
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
If you are age 50 or older and have had a heart attack, you might be eligible to take part in a government study testing the
effectiveness and safety of chelation therapy, an investigational treatment for people with heart disease. The study,
sponsored by the National Institutes of Health, is the largest of its kind. Almost 2,000 people at more than 100 medical
institutions across the country will take part in the study.
Currently, 13 million Americans have heart disease. It is the leading cause of death in the United States, and in Washington
State, it claims the lives of 11,141 people every year.
Chelation therapy (pronounced key-LAY-shun) is a process in which a synthetic or man-made amino acid called EDTA
(ethylene diamine tetra-acetic acid) is delivered intravenously. EDTA binds with molecules, such as metals or minerals, and
holds them tightly so that they can be removed from the body. Some people are already considering chelation therapy to
treat their heart disease, despite the fact that previous studies were too small to be conclusive. However, this study is 20
times larger than previous studies and is designed to find out if chelation therapy and/or high-dose vitamin therapy is a safe
and effective treatment option for people with heart disease.
“It is important for people with heart disease to know whether chelation therapy should be added to the list of proven
treatments for heart disease,” said Gervasio A. Lamas, M.D., principal investigator of the study and director of
cardiovascular research and academic affairs at Mount Sinai Medical Center in Miami Beach, Florida. “This study will help
us definitively answer that critical question.”
The Center for Optimal Health is seeking men and women age 50 and older who have had a heart attack to join a National
Institutes of Health (NIH) study on the effectiveness and safety of an investigational treatment for heart disease. The
investigational treatment is a combination of chelation therapy and high-dose vitamin therapy compared with a placebo
(inactive treatment).
There is no cost to participate in the study and participants will be closely monitored to ensure they receive the optimal
standard of care for their heart disease, such as vitamin supplements and advice on lifestyle and diet. Participants will be
randomly assigned to receive: either chelation therapy or placebo (saline) solution and either high-dose vitamin therapy or
placebo pills. All participants will also receive low-dose vitamins.
The study is co-funded by the National Center for Complementary and Alternative Medicine (NCCAM) and the National
Heart, Lung, and Blood Institute, both part of the NIH, the government’s lead agency for medical research.
More information about the study is available at the NCCAM Web site at www.nccam.nih.gov/chelation or by calling 1-888-
644-6226.
“I don’t want to leave any stone unturned as we look for ways to address heart disease,” said Dr. Lamas. “And I don’t think
patients living with heart disease want us to either.”
effectiveness and safety of chelation therapy, an investigational treatment for people with heart disease. The study,
sponsored by the National Institutes of Health, is the largest of its kind. Almost 2,000 people at more than 100 medical
institutions across the country will take part in the study.
Currently, 13 million Americans have heart disease. It is the leading cause of death in the United States, and in Washington
State, it claims the lives of 11,141 people every year.
Chelation therapy (pronounced key-LAY-shun) is a process in which a synthetic or man-made amino acid called EDTA
(ethylene diamine tetra-acetic acid) is delivered intravenously. EDTA binds with molecules, such as metals or minerals, and
holds them tightly so that they can be removed from the body. Some people are already considering chelation therapy to
treat their heart disease, despite the fact that previous studies were too small to be conclusive. However, this study is 20
times larger than previous studies and is designed to find out if chelation therapy and/or high-dose vitamin therapy is a safe
and effective treatment option for people with heart disease.
“It is important for people with heart disease to know whether chelation therapy should be added to the list of proven
treatments for heart disease,” said Gervasio A. Lamas, M.D., principal investigator of the study and director of
cardiovascular research and academic affairs at Mount Sinai Medical Center in Miami Beach, Florida. “This study will help
us definitively answer that critical question.”
The Center for Optimal Health is seeking men and women age 50 and older who have had a heart attack to join a National
Institutes of Health (NIH) study on the effectiveness and safety of an investigational treatment for heart disease. The
investigational treatment is a combination of chelation therapy and high-dose vitamin therapy compared with a placebo
(inactive treatment).
There is no cost to participate in the study and participants will be closely monitored to ensure they receive the optimal
standard of care for their heart disease, such as vitamin supplements and advice on lifestyle and diet. Participants will be
randomly assigned to receive: either chelation therapy or placebo (saline) solution and either high-dose vitamin therapy or
placebo pills. All participants will also receive low-dose vitamins.
The study is co-funded by the National Center for Complementary and Alternative Medicine (NCCAM) and the National
Heart, Lung, and Blood Institute, both part of the NIH, the government’s lead agency for medical research.
More information about the study is available at the NCCAM Web site at www.nccam.nih.gov/chelation or by calling 1-888-
644-6226.
“I don’t want to leave any stone unturned as we look for ways to address heart disease,” said Dr. Lamas. “And I don’t think
patients living with heart disease want us to either.”
| VOLUNTEERS NEEDED FOR NATIONWIDE STUDY EXAMINING INVESTIGATIONAL TREATMENT FOR HEART DISEASE |